Incannex Healthcare

Incannex Healthcare FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Incannex Healthcare (IXHL) as of Oct 24, 2026 is 26.71 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 87.34 % — a change of -69.42% (lower).

FCF Conversion

26.71 %

YoY

-69.42%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Incannex Healthcare is 2025 26.71 % . FCF Conversion Rate (FCF/EBITDA) of Incannex Healthcare was 2024 87.34 % . It decreases by -69.42% lower compared to the previous year.

The Incannex Healthcare FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
98.32 USD
Jan 1, 2019
80.38 USD
Jan 1, 2020
83.18 USD
Jan 1, 2021
60.76 USD
Jan 1, 2022
85.93 USD
Jan 1, 2023
22.67 USD
Jan 1, 2024
87.34 USD
Jan 1, 2025
26.71 USD
The Incannex Healthcare FCF Conversion history
YEARFCF ConversionYoY
26.71 %-69.42%
87.34 %+285.28%
22.67 %-73.62%
85.93 %+41.43%
60.76 %-26.95%
83.18 %+3.49%
80.38 %-18.25%
98.32 %+643.73%
13.22 %-88.56%
115.57 %+148.47%
46.51 %-1,558.75%
-3.19 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Incannex Healthcare Stock analysis

What does Incannex Healthcare do? Incannex Healthcare Inc develops medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for various medical conditions including obstructive sleep apnea, traumatic brain injury, and inflammatory diseases. The company operates with 28 distinct R&D programs and six ongoing clinical trials, focusing on treatments for conditions such as OSA, TBI, ARDS, COPD, rheumatoid arthritis, and anxiety disorders. Its portfolio includes specific clinical projects like IHL-42X for OSA, IHL-675A for lung and joint inflammation, IHL-216A for concussion and TBI, PSI-GAD for anxiety, and MedChew GB and MedChew -1401 for pain management. Incannex generates revenue through the development and potential commercialization of these pharmaceutical products, targeting healthcare providers and patients seeking innovative treatments for complex medical conditions. The company's primary revenue streams come from the progression of its R&D pipeline, with key products in clinical stages including IHL-42X, IHL-675A, IHL-216A, PSI-GAD, MedChew GB, and MedChew -1401. These products are developed for specific medical indications, such as obstructive sleep apnea, inflammatory lung diseases, rheumatoid arthritis, and pain disorders. Incannex's business model relies on securing funding through clinical trial partnerships and potential future licensing agreements with pharmaceutical companies, aiming to bring these therapies to market for patients requiring advanced treatment options. Incannex Healthcare Inc targets healthcare providers and patients in the pharmaceutical sector who are seeking novel therapies for conditions like sleep apnea, chronic pain, and inflammatory disorders. The company's diversified R&D portfolio, with six active clinical trials, positions it to address multiple unmet medical needs across various therapeutic areas. By focusing on cannabinoid-based and psychedelic medicine approaches, Incannex differentiates itself in the pharmaceutical market, aiming to provide innovative solutions for complex health challenges. Incannex Healthcare is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Incannex Healthcare stock

FCF Conversion Rate (FCF/EBITDA) of Incannex Healthcare is 26.71 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Incannex Healthcare changed from 87.34 % to 26.71 %, representing a -69.42% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Incannex Healthcare since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Incannex Healthcare with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Incannex Healthcare

All Key Metrics — Incannex Healthcare